- Alivus Life Sciences reported its highest-ever quarterly revenue of Rs. 6,729 Mn in Q3FY26, with EBITDA margins reaching a record 36.4%.
- The company cited recovery in its CDMO business, new product launches, and operational efficiencies as key drivers of performance.
Alivus Life Sciences Limited has announced its financial results for the quarter and nine months ended December 31, 2025, reporting record quarterly revenue and margin expansion. For Q3FY26, revenue from operations reached Rs. 6,729 Mn, representing growth of 14.4% quarter-on-quarter and 4.8% year-on-year.
EBITDA for the quarter stood at Rs. 2,452 Mn, up 26.5% QoQ and 22.1% YoY, with EBITDA margins rising to a record 36.4%. The company attributed the performance to a favourable product mix following recovery in its CDMO business, higher contributions from new product launches, and continued gains in operational efficiency. Profit after tax for Q3FY26 was Rs. 1,503 Mn, a growth of 15.5% QoQ and 9.7% YoY.
For the nine months ended December 31, 2025, revenue from operations totalled Rs. 18,627 Mn, reflecting year-on-year growth of 7.2%. EBITDA for the period reached Rs. 6,204 Mn, up 22.0% YoY, with margins improving to 33.3%. PAT for 9MFY26 stood at Rs. 4,019 Mn, representing growth of 16.9% YoY.
The company also reported strong cash generation, with free cash flow of Rs. 2,207 Mn during 9MFY26, resulting in cash and cash equivalents of Rs. 7,330 Mn as of December 31, 2025. Cumulative DMF and CEP filings reached 595 across major markets, while construction continued at the Solapur site for additional API capacity.
“This quarter showed a clear improvement in our operating performance. The CDMO business recovered as expected, delivering the turnaround we had planned for in the second half of the year.”
Dr. Yasir Rawjee, MD & CEO of Alivus Life Sciences Limited
